

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
28 February 2008 (28.02.2008)

PCT

(10) International Publication Number
WO 2008/024892 A2

(51) International Patent Classification:

C07C 57/50 (2006.01) **C07C 61/40** (2006.01)
C07C 57/62 (2006.01) **C07C 59/54** (2006.01)
C07C 59/56 (2006.01) **C07D 203/18** (2006.01)
C07C 59/72 (2006.01) **C07D 205/04** (2006.01)
C07C 59/88 (2006.01) **C07D 205/08** (2006.01)
C07C 61/39 (2006.01) **C07D 263/04** (2006.01)

Bristol-Myers Squibb Company, 1 Squibb Drive, New Brunswick, NJ 08903 (US). **GUO, Zhiwei** [US/US]; c/o Bristol-Myers Squibb Company, 1 Squibb Drive, New Brunswick, NJ 08903 (US). **PATEL, Ramesh N.** [US/US]; c/o Bristol-Myers Squibb Company, 1 Squibb Drive, New Brunswick, NJ 08903 (US).

(21) International Application Number:

PCT/US2007/076593

(22) International Filing Date: 23 August 2007 (23.08.2007)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/840,071 24 August 2006 (24.08.2006) US
 11/843,015 22 August 2007 (22.08.2007) US

(71) Applicant (for all designated States except US): **BRISTOL-MYERS SQUIBB COMPANY** [US/US]; P.O. Box 4000, Route 206 and ProvinceLine Road, Princeton, NJ 08543-4000 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **YE, Xiang-yang** [CN/US]; c/o Bristol-Myers Squibb Company, 311 Pennington-Rocky Hill Road, Pennington, NJ 08534 (US). **ROBL, Jeffrey A.** [US/US]; c/o Bristol-Myers Squibb Company, 311 Pennington-Rocky Hill Road, Pennington, NJ 08534 (US). **HANSON, Ronald L.** [US/US]; c/o

(74) Agents: **BOGIE, Terence J.** et al.; Bristol-Myers Squibb Company, P.O. Box 4000, Princeton, NJ 08543-4000 (US).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

(54) Title: CYCLIC 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS



(I)

(57) Abstract: Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-Beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds have the structure (I) enantiomers, diastereomers, solvates, or salts thereof, wherein A, W, X and Z are defined herein.